Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. Mukai R, Matsumoto H, Akiyama H. PLoS One 2021;16:e0259879.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One 2021;16:e0259879.
PMID: 34871313